RT Journal Article
T1 Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study.
A1 Muñoz-Martínez, Sergio
A1 Sapena, Victor
A1 Forner, Alejandro
A1 Bruix, Jordi
A1 Sanduzzi-Zamparelli, Marco
A1 Ríos, José
A1 Bouattour, Mohamed
A1 El-Kassas, Mohamed
A1 Leal, Cassia R G
A1 Mocan, Tudor
A1 Nault, Jean-Charles
A1 Alves, Rogerio C P
A1 Reeves, Helen L
A1 da Fonseca, Leonardo
A1 García-Juárez, Ignacio
A1 Pinato, David J
A1 Varela, María
A1 Alqahtani, Saleh A
A1 Alvares-da-Silva, Mario R
A1 Bandi, Juan C
A1 Rimassa, Lorenza
A1 Lozano, Mar
A1 González Santiago, Jesús M
A1 Tacke, Frank
A1 Sala, Margarita
A1 Anders, María
A1 Lachenmayer, Anja
A1 Piñero, Federico
A1 França, Alex
A1 Guarino, Maria
A1 Elvevi, Alessandra
A1 Cabibbo, Giuseppe
A1 Peck-Radosavljevic, Markus
A1 Rojas, Ángela
A1 Vergara, Mercedes
A1 Braconi, Chiara
A1 Pascual, Sonia
A1 Perelló, Christie
A1 Mello, Vivianne
A1 Rodríguez-Lope, Carlos
A1 Acevedo, Juan
A1 Villani, Rosanna
A1 Hollande, Clemence
A1 Vilgrain, Valérie
A1 Tawheed, Ahmed
A1 Ferguson Theodoro, Carmem
A1 Sparchez, Zeno
A1 Blaise, Lorraine
A1 Viera-Alves, Daniele E
A1 Watson, Robyn
A1 Carrilho, Flair J
A1 Moctezuma-Velázquez, Carlos
A1 D'Alessio, Antonio
A1 Iavarone, Massimo
A1 Reig, Maria
K1 COVID-19
K1 hepatocellular carcinoma
K1 liver cancer
K1 mortality
AB Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population. Multicentre retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February and December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered. Two hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts respectively. Patients had advanced cancer stage at SARS-CoV-2 diagnosis in 39.0% of the HCC and 71.9% of the iCCA patients. After a median follow-up of 7.20 (IQR: 1.84-11.24) months, 100 (40%) patients have died, 48% of the deaths were SARS-CoV-2-related. Forty (18.4%) HCC patients died within 30-days. The death rate increase was significantly different according to the BCLC stage (6.10% [95% CI 2.24-12.74], 11.76% [95% CI 4.73-22.30], 20.69% [95% CI 11.35-31.96] and 34.52% [95% CI 17.03-52.78] for BCLC 0/A, B, C and D, respectively; p = .0017). The hazard ratio was 1.45 (95% CI 0.49-4.31; p = .5032) in BCLC-B versus 0/A, and 3.13 (95% CI 1.29-7.62; p = .0118) in BCLC-C versus 0/A in the competing risk Cox regression model. Nineteen out of 32 iCCA (59.4%) died, and 12 deaths were related to SARS-CoV-2 infection. This is the largest cohort of liver cancer patients infected with SARS-CoV-2. It characterizes the 30-day mortality risk of SARS-CoV-2 infected patients with HCC during this period.
YR 2022
FD 2022-06-23
LK http://hdl.handle.net/10668/20006
UL http://hdl.handle.net/10668/20006
LA en
DS RISalud
RD Apr 7, 2025